Frakefamide

Clinical data
Other names	L-Tyrosyl-D-alanyl-4-fluoro-L-phenylalanyl-L-phenylalaninamide
ATC code	None
Identifiers
IUPAC name (2S)-2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-[(1S)-1-carbamoyl-2-phenylethyl]-3-(4-fluorophenyl)propanamide
CAS Number	188196-22-7
PubChemCID	9829352
ChemSpider	8005088
UNII	DM32B4GU70
CompTox Dashboard(EPA)	DTXSID701030318
Chemical and physical data
Formula	C30H34FN5O5
Molar mass	563.630 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
InChI InChI=1S/C30H34FN5O5/c1-18(34-29(40)24(32)15-20-9-13-23(37)14-10-20)28(39)36-26(17-21-7-11-22(31)12-8-21)30(41)35-25(27(33)38)16-19-5-3-2-4-6-19/h2-14,18,24-26,37H,15-17,32H2,1H3,(H2,33,38)(H,34,40)(H,35,41)(H,36,39)/t18-,24+,25+,26+/m1/s1 Key:GTPHQORJKFJIRB-JTQLPTLWSA-N

Frakefamide (INN) is asynthetic,fluorinated linear tetrapeptide with theamino acid sequence Tyr-D-Ala-(p-F)Phe-Phe-NH₂ which acts as aperipherally-specific,selectiveμ-opioid receptoragonist.^[1][2] Despite its inability to penetrate theblood-brain-barrier and enter thecentral nervous system,^[1] frakefamide haspotentanalgesic effects and, unlike centrally-acting opioids likemorphine, does not producerespiratory depression, indicating that itsantinociceptive effects are mediated by peripheral μ-opioid receptors.^[1][3] It was under development for the treatment ofpain byAstraZeneca andShire but was shelved afterphase IIclinical trials.^[4][5]

See also

• Casokefamide
• Metkefamide

References